Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade Therapy
Preclinical Data Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting Shows Highly Specific Inhibitor of TGFβ1, SRTβ1-Ab3, […]